EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity

Hyun Ji Kim iD, Jung Woo Park, Sangjae Seo, Kwang-Hwi Cho iD, Mohammed M Alanazi iD, Eun-Kyoung Bang, Gyochang Keum iD, Ashraf K El-Damasy

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Hyun Ji Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Melanoma, Quinolones. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Korea Research Fellowship Program grant through NRF funded by the Ministry of Science and ICT, National Research Council of Science & Technology (NST) grant by the Korean government (MSIT), Institutional Program grant by the Korea Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of cancer resistance to targeted therapy represents a significant challenge in cancer treatment. Therefore, identifying new anticancer candidates, particularly those addressing oncogenic mutants, is an urgent medical demand. A campaign of structural modifications has been conducted to further optimize our previously reported 2-anilinoquinoline-diarylamides conjugate VII as a B-RAFV600E/C-RAF inhibitor. Considering the incorporation of a methylene bridge between the terminal phenyl and cyclic diamine, focused quinoline-based arylamides have been tailored, synthesized, and biologically evaluated. Among them, the 5/6-hydroxyquinolines 17b and 18a stood out as the most potent members, with IC50 values of 0.128 µM, 0.114 µM against B-RAFV600E, and 0.0653 µM, 0.0676 µM against C-RAF. Most importantly, 17b elicited remarkable inhibitory potency against the clinically resistant B-RAFV600K mutant with an IC50 value of 0.0616 µM. The putative binding mode of 17b and 18a were studied by molecular docking and molecular dynamics (MD). Moreover, the antiproliferative activity of all target compounds has been examined over a panel of NCI-60 human cancer cell lines. In agreement with cell-free assays, the designed compounds exerted superior anticancer impact over the lead quinoline VII against all cell lines at a 10 µM dose. Notably, both 17b and 18b showed highly potent antiproliferative activity against melanoma cell lines with growth percent under −90% (SK-MEL-29, SK-MEL-5, and UACC-62) at a single dose, while 17b maintained potency with GI50 values of 1.60–1.89 µM against melanoma cell lines. Taken together, 17b, a promising B-RAFV600E/V600K and C-RAF kinase inhibitor, may serve as a valuable candidate in the arsenal of anticancer chemotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsMelanomaQuinolonesHumansCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorMolecular Docking SimulationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafStructure-Activity Relationship

Stichwörter der Autor:innen

B-RAFV600EB-RAFV600KC-RAF kinaseanticancer activitydiarylamidesquinolines

Substanzen

Antineoplastic AgentsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafQuinolonesBRAF protein, human

Autor:innen und Institutionen

  • Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
  • Supercomputing Application Center, Division of National Supercomputing, Korea Institute of Science and Technology Information, Daejeon 34141, Republic of Korea.
  • School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11421, Saudi Arabia.
  • Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Republic of Korea.

ORCID-Profile: Hyun Ji Kim, Kwang-Hwi Cho, Mohammed M Alanazi, Gyochang Keum

Förderung

  • the Korea Research Fellowship Program grant through NRF funded by the Ministry of Science and ICT
  • National Research Council of Science & Technology (NST) grant by the Korean government (MSIT)
  • Institutional Program grant by the Korea Institute of Science and Technology
  • Korea Research Fellowship Program
  • Researchers Supporting Project

Zitieren

APA

Kim, H. J., Park, J. W., Seo, S., Cho, K. H., Alanazi, M. M., Bang, E. K., Keum, G., & El-Damasy, A. K. (2023). Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043216

Vancouver

Kim HJ, Park JW, Seo S, Cho KH, Alanazi MM, Bang EK, et al. Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043216

BibTeX
@article{Kim2023,
  author = {Kim, Hyun Ji and Park, Jung Woo and Seo, Sangjae and Cho, Kwang-Hwi and Alanazi, Mohammed M and Bang, Eun-Kyoung and Keum, Gyochang and El-Damasy, Ashraf K},
  title = {Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043216}
}
Kostenlos starten →